Erudio Healtherudio.com
Congress · Oct 23–27, 2026 · past meeting
ESMO Congress 2026
Trials whose public commentary places their results at ESMO Congress 2026, Oct 23–27, 2026. A trial is listed only when at least two public sources, from two publishers, place its results or presentation at the meeting; each row says how many did.
105 trials: 31 with reports and 74 with no report yet. Organised by European Society for Medical Oncology (ESMO); Erudio is not affiliated with it.
Focused$750Standard$1,250Deep$1,950Pricing
Reports: each is priced by its size, licensed permanently for your organization's internal use, with MCP access for your AI agent. Buy on the report's page. Team and enterprise access
Published reports · 31
What clinicians said about each trial in public, every statement linked to its source. Counts: verified statements, and how many of them come from speakers whose clinical role the NPI registry or their institution's staff page confirms.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| Advanced solid tumors · 3 | |||||||
| KANDLELIT-001 calderasib (MK-1084); calderasib (MK-1084) plus pembrolizumab; calderasib (MK-1084) plus cetuximab placed at ESMO Congress 2026 by 4 sources NCT05067283 · Merck Sharp & Dohme LLC | KRAS G12C-mutant advanced solid tumors | Phase 1 | 52 | 18 | Focused | Oct 31, 2026 | Preview |
| BEHOLD-1 mocertatug rezetecan placed at ESMO Congress 2026 by 3 sources NCT06431594 · GlaxoSmithKline | advanced solid tumors | Phase 1 | 100 | 24 | Focused | Oct 31, 2026 | Preview |
| M21-404 telisotuzumab adizutecan (ABBV-400); telisotuzumab adizutecan (ABBV-400) plus bevacizumab placed at ESMO Congress 2026 by 3 sources NCT05029882 · AbbVie | advanced solid tumors | Phase 1 | 152 | 61 | Standard | Nov 2, 2026 | Preview |
| Biliary tract cancer · 1 | |||||||
| ACTICCA-1 gemcitabine plus cisplatin placed at ESMO Congress 2026 by 9 sources NCT02170090 · Universitätsklinikum Hamburg-Eppendorf | biliary tract cancer after curative intent resection | Phase 3 | 79 | 29 | Focused | Nov 1, 2026 | Preview |
| Breast cancer · 4 | |||||||
| FOURLIGHT-1 atirmociclib (PF-07220060) plus fulvestrant placed at ESMO Congress 2026 by 25 sources NCT06105632 · Pfizer | HR-positive/HER2-negative advanced/metastatic breast cancer after CDK4/6 inhibitor-based therapy | Phase 2 | 94 | 49 | Focused | Nov 1, 2026 | Preview |
| KEYNOTE-B49 pembrolizumab placed at ESMO Congress 2026 by 24 sources NCT04895358 · Merck Sharp & Dohme LLC | HR+/HER2- locally recurrent inoperable or metastatic breast cancer | Phase 3 | 74 | 40 | Focused | Oct 31, 2026 | Preview |
| APEX-Breast01 TQB2102 placed at ESMO Congress 2026 by 5 sources NCT06561607 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | HER2 low-expressing recurrent/metastatic breast cancer | Phase 3 | 40 | 12 | Focused | Nov 4, 2026 | Preview |
| HER2 CR Tests a strategy, not a drug placed at ESMO Congress 2026 by 3 sources NCT06663787 · Nagoya City University | HER2-positive metastatic breast cancer | Observational | 37 | 10 | Focused | Nov 1, 2026 | Preview |
| Colorectal cancer · 2 | |||||||
| ECLYPse encorafenib plus cetuximab plus FOLFIRI placed at ESMO Congress 2026 by 8 sources NCT06640166 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS | BRAF V600E-mutated metastatic colorectal cancer | Phase 2 | 23 | 8 | Focused | Nov 2, 2026 | Preview |
| BRICKET encorafenib plus cetuximab placed at ESMO Congress 2026 by 5 sources NCT06578559 · Gruppo Oncologico del Nord-Ovest | BRAF V600E-mutated metastatic colorectal cancer | Phase 2 | 21 | 11 | Focused | Oct 28, 2026 | Preview |
| Gastroesophageal adenocarcinoma · 1 | |||||||
| G-HOPE-001 arcotatug tavatecan (IBI343) placed at ESMO Congress 2026 by 18 sources NCT06238843 · Innovent Biologics (Suzhou) Co. Ltd. | CLDN18.2-positive HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma | Phase 3 | 99 | 26 | Focused | Nov 1, 2026 | Preview |
| Gastroesophageal junction cancer · 1 | |||||||
| KEYNOTE-975 pembrolizumab placed at ESMO Congress 2026 by 10 sources NCT04210115 · Merck Sharp & Dohme LLC | esophageal or gastroesophageal junction carcinoma | Phase 3 | 174 | 27 | Standard | Nov 1, 2026 | Preview |
| Head and neck squamous cell carcinoma · 1 | |||||||
| RADIAN niraparib plus dostarlimab plus cisplatin; niraparib plus dostarlimab placed at ESMO Congress 2026 by 3 sources NCT05784012 · Grupo Español de Tratamiento de Tumores de Cabeza y Cuello | locally advanced head and neck squamous cell carcinoma | Phase 1/Phase 2 | 19 | 8 | Focused | Oct 29, 2026 | Preview |
| Non-small cell lung cancer · 12 | |||||||
| Krascendo 1 divarasib placed at ESMO Congress 2026 by 54 sources NCT06497556 · Hoffmann-La Roche | previously treated KRAS G12C-positive non-small cell lung cancer | Phase 3 | 314 | 153 | Deep | Nov 1, 2026 | Preview |
| PERSEE pembrolizumab plus platinum-based chemotherapy placed at ESMO Congress 2026 by 28 sources NCT04547504 · University Hospital, Brest | first-line advanced NSCLC with PD-L1 ≥50% | Phase 3 | 217 | 73 | Standard | Nov 3, 2026 | Preview |
| SARON Tests a strategy, not a drug placed at ESMO Congress 2026 by 19 sources NCT02417662 · University College, London | oligometastatic non-small cell lung cancer | Not applicable | 315 | 80 | Deep | Nov 1, 2026 | Preview |
| SANOVO savolitinib plus osimertinib placed at ESMO Congress 2026 by 13 sources NCT05009836 · Hutchmed | first-line EGFRm+/MET+ locally advanced or metastatic NSCLC | Phase 3 | 90 | 55 | Focused | Oct 27, 2026 | Preview |
| PANKU-Lung01 izalontamab brengitecan (BL-B01D1) placed at ESMO Congress 2026 by 9 sources NCT06382116 · Sichuan Baili Pharmaceutical Co., Ltd. | advanced non-small cell lung cancer after EGFR-TKI failure | Phase 3 | 97 | 35 | Focused | Nov 4, 2026 | Preview |
| SigVie-002 sigvotatug vedotin placed at ESMO Congress 2026 by 8 sources NCT06012435 · Seagen, a wholly owned subsidiary of Pfizer | previously treated non-small cell lung cancer | Phase 3 | 64 | 24 | Focused | Nov 2, 2026 | Preview |
| HERON-Lung01 ruzaltatug rezetecan placed at ESMO Congress 2026 by 7 sources NCT06671379 · Suzhou Suncadia Biopharmaceuticals Co., Ltd. | EGFR-mutated advanced or metastatic NSCLC after TKI failure | Phase 3 | 34 | 12 | Focused | Nov 1, 2026 | Preview |
| ROSETTA Lung-107 pumitamig plus docetaxel placed at ESMO Congress 2026 by 7 sources NCT06841055 · BioNTech SE | first- or second-line non-small cell lung cancer | Phase 2 | 13 | 4 | Focused | Nov 1, 2026 | Preview |
| DIAL pembrolizumab placed at ESMO Congress 2026 by 6 sources NCT05255302 · Intergroupe Francophone de Cancerologie Thoracique | metastatic NSCLC | Phase 2/Phase 3 | 29 | 15 | Focused | Oct 28, 2026 | Preview |
| OptiTROP-Lung06 sacituzumab tirumotecan plus pembrolizumab placed at ESMO Congress 2026 by 5 sources NCT06711900 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | first-line PD-L1-negative advanced non-squamous non-small cell lung cancer | Phase 3 | 13 | 8 | Focused | Oct 29, 2026 | Preview |
| PACE-LUNG osimertinib plus pemetrexed plus platinum-based chemotherapy placed at ESMO Congress 2026 by 3 sources NCT05281406 · Goethe University | EGFRm NSCLC with continued presence of plasma ctDNA | Phase 2 | 76 | 16 | Focused | Oct 28, 2026 | Preview |
| ARTEMIDE-01 rilvegostomig placed at ESMO Congress 2026 by 2 sources NCT04995523 · AstraZeneca | advanced or metastatic NSCLC | Phase 1/Phase 2 | 53 | 15 | Focused | Oct 29, 2026 | Preview |
| Pancreatic cancer · 1 | |||||||
| MAPKeeper 301 atebimetinib placed at ESMO Congress 2026 by 3 sources NCT07562152 · Immuneering Corporation | first-line metastatic pancreatic ductal adenocarcinoma | Phase 3 | 138 | 37 | Focused | Nov 1, 2026 | Preview |
| Prostate cancer · 1 | |||||||
| LIBERTAS apalutamide placed at ESMO Congress 2026 by 2 sources NCT05884398 · Janssen Research & Development, LLC | metastatic castration-sensitive prostate cancer | Phase 3 | 813 | 56 | Deep | Nov 3, 2026 | Preview |
| Renal cell carcinoma · 2 | |||||||
| XmAb819-01 XmAb819 placed at ESMO Congress 2026 by 16 sources NCT05433142 · Xencor, Inc. | relapsed or refractory clear cell renal cell carcinoma | Phase 1 | 294 | 87 | Standard | Nov 3, 2026 | Preview |
| PE-PE pembrolizumab placed at ESMO Congress 2026 by 6 sources NCT05578664 · Consorzio Oncotech | oligometastatic renal cell carcinoma | Phase 2 | 35 | 13 | Focused | Oct 29, 2026 | Preview |
| Other · 2 | |||||||
| AMPLIFY-7P ELI-002 7P placed at ESMO Congress 2026 by 14 sources NCT05726864 · Elicio Therapeutics | KRAS/NRAS-mutated solid tumors | Phase 1/Phase 2 | 255 | 75 | Standard | Nov 4, 2026 | Preview |
| DEWI dostarlimab placed at ESMO Congress 2026 by 12 sources NCT06059495 · GERCOR - Multidisciplinary Oncology Cooperative Group | localized dMMR/MSI-H gastric/GEJ adenocarcinoma | Phase 2 | 18 | 10 | Focused | Oct 29, 2026 | Preview |
No report yet · 74
Trial pages with the registry record and the public commentary we have indexed so far. The report is built on order from the trial page. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| Advanced solid tumors · 3 | |||||||
| LOXO-RAS-20001 olomorasib (LY3537982); olomorasib (LY3537982) plus pembrolizumab; olomorasib (LY3537982) plus cetuximab placed at ESMO Congress 2026 by 4 sources NCT04956640 · Eli Lilly and Company DeepView → | KRAS G12C-mutant advanced solid tumors | Phase 1/Phase 2 | Deep | View | |||
| INT-101-01 tambotatug pelitecan (YL201); tambotatug pelitecan (YL201) plus atezolizumab placed at ESMO Congress 2026 by 2 sources NCT05434234 · MediLink Therapeutics (Suzhou) Co., Ltd. FocusedView → | advanced solid tumors | Phase 1/Phase 2 | Focused | View | |||
| START-001 Drug not named yet placed at ESMO Congress 2026 by 2 sources NCT05592626 · Marengo Therapeutics, Inc. FocusedView → | antigen-rich advanced solid tumors | Phase 1/Phase 2 | Focused | View | |||
| Biliary tract cancer · 2 | |||||||
| HARMONi-GI1 ivonescimab (AK112) placed at ESMO Congress 2026 by 21 sources NCT06591520 · Akeso DeepView → | first-line advanced biliary tract cancer | Phase 3 | Deep | View | |||
| COMPANION-002 tovecimig (CTX-009) placed at ESMO Congress 2026 by 16 sources NCT05506943 · Compass Therapeutics DeepView → | advanced biliary tract cancer after one prior regimen | Phase 2/Phase 3 | Deep | View | |||
| Breast cancer · 11 | |||||||
| NATALEE ribociclib placed at ESMO Congress 2026 by 40 sources NCT03701334 · Novartis Pharmaceuticals DeepView → | HR+/HER2- early breast cancer | Phase 3 | Deep | View | |||
| TROPION-Breast02 datopotamab deruxtecan placed at ESMO Congress 2026 by 22 sources NCT05374512 · AstraZeneca DeepView → | first-line inoperable or metastatic triple-negative breast cancer | Phase 3 | Deep | View | |||
| postMONARCH abemaciclib placed at ESMO Congress 2026 by 16 sources NCT05169567 · Eli Lilly and Company DeepView → | HR+, HER2- advanced or metastatic breast cancer | Phase 3 | Deep | View | |||
| DESTINY-Breast09 trastuzumab deruxtecan plus pertuzumab; trastuzumab deruxtecan placed at ESMO Congress 2026 by 12 sources NCT04784715 · AstraZeneca DeepView → | first-line HER2-positive metastatic breast cancer | Phase 3 | Deep | View | |||
| evERA giredestrant plus everolimus placed at ESMO Congress 2026 by 12 sources NCT05306340 · Genentech, Inc. DeepView → | ER-positive, HER2-negative locally advanced or metastatic breast cancer | Phase 3 | Deep | View | |||
| HORIZON-Breast06 trastuzumab rezetecan (SHR-A1811) placed at ESMO Congress 2026 by 12 sources NCT05814354 · Jiangsu HengRui Medicine Co., Ltd. DeepView → | HER2-low expressing recurrent/metastatic breast cancer | Phase 3 | Deep | View | |||
| VIKTORIA-1 gedatolisib plus palbociclib plus fulvestrant; gedatolisib plus fulvestrant placed at ESMO Congress 2026 by 5 sources NCT05501886 · Celcuity Inc DeepView → | HR+/HER2- advanced breast cancer after CDK4/6 inhibitor therapy | Phase 3 | Deep | View | |||
| DESTINY-Breast05 trastuzumab deruxtecan placed at ESMO Congress 2026 by 3 sources NCT04622319 · Daiichi Sankyo DeepView → | HER2-positive residual invasive breast cancer following neoadjuvant therapy | Phase 3 | Deep | View | |||
| DESTINY-Breast11 trastuzumab deruxtecan plus paclitaxel plus trastuzumab plus pertuzumab; trastuzumab deruxtecan placed at ESMO Congress 2026 by 2 sources NCT05113251 · AstraZeneca DeepView → | high-risk HER2-positive early-stage breast cancer | Phase 3 | Deep | View | |||
| SATEEN sacituzumab govitecan plus trastuzumab placed at ESMO Congress 2026 by 2 sources NCT06100874 · Adrienne G. Waks DeepView → | HER2+ metastatic breast cancer after trastuzumab deruxtecan | Phase 2 | Deep | View | |||
| SWITCH trastuzumab rezetecan (SHR-A1811); SHR-A1921; SHR-A2009 placed at ESMO Congress 2026 by 2 sources NCT06649331 · Fudan University FocusedView → | ADC-treated metastatic breast cancer | Phase 2 | Focused | View | |||
| Colorectal cancer · 1 | |||||||
| AZUR-1 dostarlimab placed at ESMO Congress 2026 by 9 sources NCT05723562 · GlaxoSmithKline DeepView → | untreated stage II/III dMMR/MSI-H locally advanced rectal cancer | Phase 2 | Deep | View | |||
| Endometrial cancer · 2 | |||||||
| TroFuse-005 sacituzumab tirumotecan placed at ESMO Congress 2026 by 14 sources NCT06132958 · Merck Sharp & Dohme LLC DeepView → | endometrial cancer after platinum-based chemotherapy and immunotherapy | Phase 3 | Deep | View | |||
| DUO-E durvalumab plus olaparib; durvalumab placed at ESMO Congress 2026 by 5 sources NCT04269200 · AstraZeneca DeepView → | newly diagnosed advanced or recurrent endometrial cancer | Phase 3 | Deep | View | |||
| Gastric cancer · 1 | |||||||
| KC-WISE KN026 placed at ESMO Congress 2026 by 3 sources NCT05427383 · Shanghai JMT-Bio Inc. DeepView → | HER2-positive advanced gastric cancer after failed first-line therapy | Phase 2/Phase 3 | Deep | View | |||
| Gastroesophageal adenocarcinoma · 2 | |||||||
| CLARITY-Gastric 01 sonesitatug vedotin (AZD0901) placed at ESMO Congress 2026 by 21 sources NCT06346392 · AstraZeneca DeepView → | Claudin18.2-expressing advanced gastric or gastroesophageal junction adenocarcinoma | Phase 3 | Deep | View | |||
| HERIZON-GEA-01 zanidatamab; zanidatamab plus tislelizumab placed at ESMO Congress 2026 by 10 sources NCT05152147 · Jazz Pharmaceuticals DeepView → | HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma | Phase 3 | Deep | View | |||
| Gastroesophageal junction cancer · 1 | |||||||
| FORTITUDE-101 bemarituzumab placed at ESMO Congress 2026 by 2 sources NCT05052801 · Amgen DeepView → | untreated advanced FGFR2b-overexpressing gastric or gastroesophageal junction cancer | Phase 3 | Deep | View | |||
| Head and neck squamous cell carcinoma · 1 | |||||||
| OrigAMI-4 amivantamab; amivantamab plus pembrolizumab; amivantamab plus paclitaxel placed at ESMO Congress 2026 by 5 sources NCT06385080 · Janssen Research & Development, LLC DeepView → | head and neck squamous cell carcinoma | Phase 1/Phase 2 | Deep | View | |||
| Hepatocellular carcinoma · 2 | |||||||
| EMERALD-3 durvalumab plus tremelimumab plus lenvatinib; durvalumab plus tremelimumab placed at ESMO Congress 2026 by 6 sources NCT05301842 · AstraZeneca DeepView → | locoregional hepatocellular carcinoma | Phase 3 | Deep | View | |||
| LEAP-012 lenvatinib plus pembrolizumab placed at ESMO Congress 2026 by 6 sources NCT04246177 · Merck Sharp & Dohme LLC DeepView → | incurable non-metastatic hepatocellular carcinoma | Phase 3 | Deep | View | |||
| Medullary thyroid cancer · 1 | |||||||
| LIBRETTO-531 selpercatinib placed at ESMO Congress 2026 by 5 sources NCT04211337 · Loxo Oncology, Inc. DeepView → | kinase inhibitor-naïve advanced RET-mutant medullary thyroid cancer | Phase 3 | Deep | View | |||
| Melanoma · 2 | |||||||
| INTerpath-001 intismeran autogene (V940) plus pembrolizumab placed at ESMO Congress 2026 by 97 sources NCT05933577 · Merck Sharp & Dohme LLC DeepView → | high-risk stage II-IV melanoma | Phase 3 | Deep | View | |||
| NADINA ipilimumab plus nivolumab placed at ESMO Congress 2026 by 3 sources NCT04949113 · The Netherlands Cancer Institute StandardView → | macroscopic resectable stage III melanoma | Phase 3 | Standard | View | |||
| Non-small cell lung cancer · 9 | |||||||
| FLAURA2 osimertinib plus pemetrexed plus platinum-based chemotherapy placed at ESMO Congress 2026 by 10 sources NCT04035486 · AstraZeneca DeepView → | first-line EGFR-mutated advanced non-small cell lung cancer | Phase 3 | Deep | View | |||
| DESTINY-Lung04 trastuzumab deruxtecan placed at ESMO Congress 2026 by 5 sources NCT05048797 · AstraZeneca DeepView → | first-line HER2 exon 19/20-mutated advanced non-squamous NSCLC | Phase 3 | Deep | View | |||
| MDT-BRIDGE durvalumab plus platinum-based chemotherapy placed at ESMO Congress 2026 by 5 sources NCT05925530 · AstraZeneca DeepView → | resectable or borderline resectable stage IIB–IIIB NSCLC | Phase 2 | Deep | View | |||
| NeoCOAST-2 oleclumab plus durvalumab plus platinum doublet chemotherapy; monalizumab plus durvalumab plus platinum doublet chemotherapy; volrustomig plus platinum doublet chemotherapy placed at ESMO Congress 2026 by 4 sources NCT05061550 · AstraZeneca DeepView → | resectable stage II–IIIB non-small cell lung cancer | Phase 2 | Deep | View | |||
| COCOON Drug not named yet placed at ESMO Congress 2026 by 3 sources NCT06120140 · Janssen Research & Development, LLC FocusedView → | first-line EGFR-mutated advanced NSCLC | Phase 2 | Focused | View | |||
| KEYNOTE-091 pembrolizumab placed at ESMO Congress 2026 by 3 sources NCT02504372 · Merck Sharp & Dohme LLC DeepView → | resected stage IB-IIIA non-small-cell lung cancer | Phase 3 | Deep | View | |||
| Neotorch toripalimab placed at ESMO Congress 2026 by 2 sources NCT04158440 · Shanghai Junshi Bioscience Co., Ltd. DeepView → | resectable stage II-III non-small cell lung cancer | Phase 3 | Deep | View | |||
| SAFFRON savolitinib plus osimertinib placed at ESMO Congress 2026 by 2 sources NCT05261399 · AstraZeneca FocusedView → | EGFR-mutated, MET-overexpressed/amplified locally advanced or metastatic NSCLC | Phase 3 | Focused | View | |||
| TUXEDO-3 patritumab deruxtecan placed at ESMO Congress 2026 by 2 sources NCT05865990 · MedSIR DeepView → | breast cancer/NSCLC brain metastases; solid tumor leptomeningeal disease | Phase 2 | Deep | View | |||
| Pancreatic cancer · 1 | |||||||
| RASolute 302 daraxonrasib (RMC-6236) placed at ESMO Congress 2026 by 18 sources NCT06625320 · Revolution Medicines, Inc. DeepView → | previously treated metastatic pancreatic ductal adenocarcinoma | Phase 3 | Deep | View | |||
| Prostate cancer · 6 | |||||||
| DASL-HiCaP darolutamide placed at ESMO Congress 2026 by 39 sources NCT04136353 · University of Sydney DeepView → | very high-risk clinically localised prostate cancer | Phase 3 | Deep | View | |||
| TALAPRO-3 talazoparib plus enzalutamide placed at ESMO Congress 2026 by 10 sources NCT04821622 · Pfizer DeepView → | DDR gene-mutated metastatic castration-sensitive prostate cancer | Phase 3 | Deep | View | |||
| PR.21 177Lu-PSMA-617 placed at ESMO Congress 2026 by 5 sources NCT04663997 · Canadian Cancer Trials Group DeepView → | PSMA-positive metastatic castration-resistant prostate cancer | Phase 2 | Deep | View | |||
| KEYNOTE-365 pembrolizumab plus olaparib; pembrolizumab plus docetaxel plus prednisone; pembrolizumab plus enzalutamide placed at ESMO Congress 2026 by 3 sources NCT02861573 · Merck Sharp & Dohme LLC DeepView → | metastatic castration-resistant prostate cancer | Phase 1/Phase 2 | Deep | View | |||
| ARASEC darolutamide placed at ESMO Congress 2026 by 2 sources NCT05059236 · Bayer StandardView → | metastatic hormone-sensitive prostate cancer | Phase 2 | Standard | View | |||
| LuCAB cabazitaxel plus 177Lu-PSMA-617 placed at ESMO Congress 2026 by 2 sources NCT05340374 · Peter MacCallum Cancer Centre, Australia DeepView → | metastatic castration-resistant prostate cancer | Phase 1/Phase 2 | Deep | View | |||
| Renal cell carcinoma · 5 | |||||||
| LITESPARK-012 belzutifan plus pembrolizumab plus lenvatinib; MK-1308A plus lenvatinib placed at ESMO Congress 2026 by 12 sources NCT04736706 · Merck Sharp & Dohme LLC DeepView → | first-line advanced clear cell renal cell carcinoma | Phase 3 | Deep | View | |||
| LITESPARK-011 belzutifan plus lenvatinib placed at ESMO Congress 2026 by 5 sources NCT04586231 · Merck Sharp & Dohme LLC DeepView → | advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy | Phase 3 | Deep | View | |||
| RAMPART durvalumab; durvalumab plus tremelimumab placed at ESMO Congress 2026 by 4 sources NCT03288532 · University College, London DeepView → | intermediate- or high-risk resected renal cell carcinoma | Phase 3 | Deep | View | |||
| KEYNOTE-564 pembrolizumab placed at ESMO Congress 2026 by 2 sources NCT03142334 · Merck Sharp & Dohme LLC DeepView → | clear cell renal cell carcinoma post-nephrectomy | Phase 3 | Deep | View | |||
| PAPMET2 atezolizumab plus cabozantinib placed at ESMO Congress 2026 by 2 sources NCT05411081 · National Cancer Institute (NCI) DeepView → | advanced papillary renal cell carcinoma | Phase 2 | Deep | View | |||
| Small cell lung cancer · 4 | |||||||
| DeLLphi-305 tarlatamab plus durvalumab placed at ESMO Congress 2026 by 96 sources NCT06211036 · Amgen DeepView → | first-line extensive-stage small-cell lung cancer | Phase 3 | Deep | View | |||
| ASTRIDE serplulimab placed at ESMO Congress 2026 by 7 sources NCT05468489 · Shanghai Henlius Biotech DeepView → | previously untreated extensive-stage small cell lung cancer | Phase 3 | Deep | View | |||
| DeLLphi-304 tarlatamab placed at ESMO Congress 2026 by 3 sources NCT05740566 · Amgen DeepView → | relapsed small cell lung cancer | Phase 3 | Deep | View | |||
| IMforte Drug not named yet placed at ESMO Congress 2026 by 3 sources NCT05091567 · Hoffmann-La Roche DeepView → | extensive-stage small-cell lung cancer | Phase 3 | Deep | View | |||
| Urothelial carcinoma · 8 | |||||||
| VOLGA durvalumab plus tremelimumab plus enfortumab vedotin; durvalumab plus enfortumab vedotin placed at ESMO Congress 2026 by 70 sources NCT04960709 · AstraZeneca DeepView → | cisplatin-ineligible muscle-invasive bladder cancer | Phase 3 | Deep | View | |||
| KEYNOTE-866 pembrolizumab placed at ESMO Congress 2026 by 22 sources NCT03924856 · Merck Sharp & Dohme LLC DeepView → | cisplatin-eligible muscle-invasive bladder cancer | Phase 3 | Deep | View | |||
| KEYNOTE-B15 enfortumab vedotin plus pembrolizumab placed at ESMO Congress 2026 by 22 sources NCT04700124 · Merck Sharp & Dohme LLC DeepView → | cisplatin-eligible muscle-invasive bladder cancer | Phase 3 | Deep | View | |||
| KEYNOTE-905 enfortumab vedotin plus pembrolizumab; pembrolizumab placed at ESMO Congress 2026 by 10 sources NCT03924895 · Merck Sharp & Dohme LLC DeepView → | cisplatin-ineligible muscle-invasive bladder cancer | Phase 3 | Deep | View | |||
| ENERGIZE nivolumab placed at ESMO Congress 2026 by 8 sources NCT03661320 · Bristol-Myers Squibb DeepView → | muscle-invasive bladder cancer | Phase 3 | Deep | View | |||
| EV-103 enfortumab vedotin plus pembrolizumab; enfortumab vedotin; enfortumab vedotin plus platinum-based chemotherapy placed at ESMO Congress 2026 by 5 sources NCT03288545 · Astellas Pharma Global Development, Inc. DeepView → | urothelial cancer | Phase 1/Phase 2 | Deep | View | |||
| GDFATHER-NEO visugromab plus nivolumab placed at ESMO Congress 2026 by 5 sources NCT06059547 · CatalYm GmbH DeepView → | muscle-invasive bladder cancer | Phase 2 | Deep | View | |||
| EV-309 enfortumab vedotin plus pembrolizumab placed at ESMO Congress 2026 by 2 sources NCT07566156 · Astellas Pharma Global Development, Inc. DeepView → | muscle-invasive bladder cancer | Phase 3 | Deep | View | |||
| Other · 12 | |||||||
| ARTEMIS-011 risvutatug rezetecan (HS-20093) placed at ESMO Congress 2026 by 17 sources NCT06935409 · Hansoh BioMedical R&D Company DeepView → | osteosarcoma after second-line treatment failure | Phase 3 | Deep | View | |||
| MOIO Drug not named yet placed at ESMO Congress 2026 by 17 sources NCT05078047 · UNICANCER DeepView → | locally advanced or metastatic cancer | Phase 3 | Deep | View | |||
| KEYNOTE-C93 pembrolizumab placed at ESMO Congress 2026 by 10 sources NCT05173987 · Merck Sharp & Dohme LLC DeepView → | first-line dMMR advanced or recurrent endometrial carcinoma | Phase 3 | Deep | View | |||
| OptiTROP-Breast01 sacituzumab tirumotecan (SKB264) placed at ESMO Congress 2026 by 6 sources NCT05347134 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. DeepView → | Not given | Phase 3 | Deep | View | |||
| OptiTROP-Lung04 sacituzumab tirumotecan (SKB264) placed at ESMO Congress 2026 by 4 sources NCT05870319 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. DeepView → | Not given | Phase 3 | Deep | View | |||
| SETHY sacituzumab tirumotecan plus tislelizumab; sacituzumab tirumotecan placed at ESMO Congress 2026 by 4 sources NCT07068542 · Zhejiang Provincial People's Hospital FocusedView → | advanced thyroid cancer | Not applicable | Focused | View | |||
| IOV-COM-202 lifileucel plus pembrolizumab; lifileucel; LN-145-S1 placed at ESMO Congress 2026 by 3 sources NCT03645928 · Iovance Biotherapeutics, Inc. FocusedView → | solid tumors | Phase 2 | Focused | View | |||
| REPRINT pembrolizumab plus enfortumab vedotin placed at ESMO Congress 2026 by 3 sources NCT06302569 · Giuseppe Procopio FocusedView → | collecting duct and renal medullary carcinoma | Phase 2 | Focused | View | |||
| ARION durvalumab placed at ESMO Congress 2026 by 2 sources NCT03777813 · UNICANCER FocusedView → | localised unresectable esophageal cancer | Phase 2 | Focused | View | |||
| iTHYM ivonescimab plus chemotherapy placed at ESMO Congress 2026 by 2 sources NCT06750952 · Sun Yat-sen University StandardView → | first-line relapsed or metastatic thymic cancer | Phase 2 | Standard | View | |||
| RINGSIDE varegacestat (AL102) placed at ESMO Congress 2026 by 2 sources NCT04871282 · Immunome, Inc. DeepView → | progressing desmoid tumors | Phase 2/Phase 3 | Deep | View | |||
| SKB264-II-06 sacituzumab tirumotecan (SKB264) plus pembrolizumab placed at ESMO Congress 2026 by 2 sources NCT05642780 · Klus Pharma Inc. StandardView → | solid tumors | Phase 2 | Standard | View | |||